For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$3.70
Thesis
Recursion Pharmaceuticals runs an industrialized, automated biology platform that generates large datasets to train machine-learning models for drug discovery. Its scale and pharma partnerships aim to convert data advantages into a clinical pipeline.
Catalysts
- Clinical-stage program readouts
- Partnership milestone and option payments
- Demonstrating platform-driven pipeline productivity
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Sep 21DealSEC
8-K item 1.01: entered into material definitive agreement.
- Aug 13Trial initiationClinicalTrials.gov
Recursion subsidiary Exscientia updates NCT05985655 Phase 1/2 trial of GTAEXS617 in advanced solid tumors to recruiting status.
- Aug 13Trial initiationClinicalTrials.gov
Exscientia (Recursion subsidiary) initiates Phase 1 dose-finding trial of EXS73565 in relapsed/refractory B-cell malignancies (NCT06980116, recruiting).
- Aug 5Financial resultsSEC
8-K filing (items 2.02, 7.01, 9.01) disclosing financial results for RXRX.
- Jun 11Trial initiationClinicalTrials.gov
Recursion subsidiary Exscientia initiates Phase 1 dose-finding trial of EXS73565 in relapsed/refractory B-cell malignancies (NCT06980116, recruiting).
- Jun 10Trial initiationClinicalTrials.gov
Recursion subsidiary Exscientia initiates Phase 1 dose-finding trial of REC-4539 in select solid tumors (NCT07517198, recruiting)
- Jun 5Trial initiationClinicalTrials.gov
Phase 1/2 trial (NCT05552755) of REC-4881 in FAP updated to recruiting status
- May 8Trial initiationClinicalTrials.gov
Recursion Pharmaceuticals lists Phase 1/2 trial of REC-1245 in unresectable or metastatic cancer as recruiting (NCT06678659)